SIGN UP FOR OUR
E-NEWSLETTER
INTERCEPT eNews delivers product news & information updates. 
INTERCEPT Plasma
Designed for efficiency & high throughput
Up to 36 treated units produced per hour per UVA illuminator; <10 minutes hands-on time; synergy with INTERCEPT Platelet treatment further improves efficiency for blood centers performing both processes.
Therapeutic performance established in controlled studies
Extensively tested in Phase III trials with approximately 5000 units transfused to patients representing all major diagnoses requiring plasma transfusion.
Robust, reproduceable and traceable
Consistent inactivation for a broad range of pathogens; processing set designed for reproducible addition and removal of amotosalen; optional IDMS software documents critical processing steps.
Learn more about INTERCEPT Plasma:
Learn more about the INTERCEPT Blood System:
- A single PI treatment for two components
- Meeting pharmaceutical registraton standards
- INTERCEPT mechanism of action
- Collection and processing information
- News and events
Use of the INTERCEPT Blood System in the United States is limited by Federal law to investigational use. If you are a resident of the U.S., please click here.
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma.
Website design by NetPilot Web Solutions